LLYD logo

Eli Lilly BATS-CHIXE:LLYD Stock Report

Last Price

€791.70

Market Cap

€721.3b

7D

-10.0%

1Y

17.9%

Updated

10 Mar, 2025

Data

Company Financials +

Eli Lilly and Company

BATS-CHIXE:LLYD Stock Report

Market Cap: €721.3b

LLYD Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. More details

LLYD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Eli Lilly and Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eli Lilly
Historical stock prices
Current Share PriceUS$791.70
52 Week HighUS$879.40
52 Week LowUS$671.50
Beta0.34
1 Month Change-5.86%
3 Month Change3.29%
1 Year Change17.90%
3 Year Changen/a
5 Year Changen/a
Change since IPO161.87%

Recent News & Updates

Recent updates

Shareholder Returns

LLYDGB PharmaceuticalsGB Market
7D-10.0%0.3%-2.7%
1Y17.9%8.9%8.8%

Return vs Industry: LLYD exceeded the UK Pharmaceuticals industry which returned 10% over the past year.

Return vs Market: LLYD exceeded the UK Market which returned 9.6% over the past year.

Price Volatility

Is LLYD's price volatile compared to industry and market?
LLYD volatility
LLYD Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement8.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.2%
10% least volatile stocks in GB Market2.7%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine LLYD's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
187647,000Dave Rickswww.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLYD fundamental statistics
Market cap€721.28b
Earnings (TTM)€9.78b
Revenue (TTM)€41.60b

70.4x

P/E Ratio

16.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLYD income statement (TTM)
RevenueUS$45.04b
Cost of RevenueUS$8.42b
Gross ProfitUS$36.62b
Other ExpensesUS$26.03b
EarningsUS$10.59b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 01, 2025

Earnings per share (EPS)11.79
Gross Margin81.31%
Net Profit Margin23.51%
Debt/Equity Ratio236.6%

How did LLYD perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

44%

Payout Ratio

Does LLYD pay a reliable dividends?

See LLYD dividend history and benchmarks
When do you need to buy LLYD by to receive an upcoming dividend?
Eli Lilly dividend dates
Ex Dividend DateFeb 14 2025
Dividend Pay DateMar 10 2025
Days until Ex dividend26 days
Days until Dividend pay date2 days

Does LLYD pay a reliable dividends?

See LLYD dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/10 19:39
End of Day Share Price 2025/03/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 55 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Luisa HectorBerenberg